Document Detail

The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery.
MedLine Citation:
PMID:  19505401     Owner:  NLM     Status:  MEDLINE    
Despite high efficacy of percutaneous coronary intervention (PCI), in-stent restenosis proves to be a significant problem of therapy. Restenosis concerns around 30 percent of patients. Studies have suggested that restenosis is initiated by cells which participate in intense inflammatory reaction caused by stent implantation. Atherosclerotic plaque rupture during stent implantation and PCI-associated injury of the vessel wall lead to hemorrhage and release of various cytokines. They are probably responsible for quick recurrence of vascular lumen stenosis (restenosis). Interleukin-6 (IL-6) is known as a main pro-inflammatory cytokine, whereas Transformig Growth Factor-beta1 (TGF-beta1) has anti-inflammatory properties. The study population comprised 36 patients with myocardial infarction treated with PCI with stent implantation. They underwent control coronary angiography after 12 months. At this time plasma concentration of IL-6 and TGF-beta was measured in peripheral blood. Serum IL-6 concentration in the analyzed population correlates with lumen loss (p<0.01) and the severity of stenosis (p<0.001). No such correlation was found between serum TGF-beta1 concentration and lumen loss (p=NS) or the severity of stenosis (p=NS). The IL-6 plasma concentration may be a marker of in-stent restenosis in patients after PTCA, while the concentration of TGF-beta1 is not associated with the occurrence of restenosis at one year of follow-up.
J Szkodzinski; A Blazelonis; K Wilczek; B Hudzik; W Romanowski; M Gasior; R Wojnar; A Lekston; L Polonski; B Zubelewicz-Szkodzinska
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of immunopathology and pharmacology     Volume:  22     ISSN:  0394-6320     ISO Abbreviation:  Int J Immunopathol Pharmacol     Publication Date:    2009 Apr-Jun
Date Detail:
Created Date:  2009-06-09     Completed Date:  2009-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8911335     Medline TA:  Int J Immunopathol Pharmacol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  493-500     Citation Subset:  IM    
3rd Dept. of Cardiology, Silesian Medical University, Zabrze, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects*,  instrumentation
Biological Markers / blood
Coronary Angiography
Coronary Restenosis / etiology,  immunology*,  radiography
Coronary Vessels / immunology*,  pathology
Interleukin-6 / blood*
Middle Aged
Myocardial Infarction / therapy*
Predictive Value of Tests
ROC Curve
Sensitivity and Specificity
Severity of Illness Index
Time Factors
Transforming Growth Factor beta1 / blood*
Treatment Outcome
Reg. No./Substance:
0/Biological Markers; 0/IL6 protein, human; 0/Interleukin-6; 0/Transforming Growth Factor beta1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancement of fibroblast proliferation, collagen biosynthesis and production of growth factors as a...
Next Document:  Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-deriv...